Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2025-02-24 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天健会计师事务所对天士力非经营性资金占用及其他关联资金往来情况的专项审计说明
Regulatory Filings
2025-02-24 Chinese
天士力关于控股子公司增资扩股暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a capital increase and equity restructuring involving a controlling subsidiary and related party transactions. It includes specifics about the transaction, parties involved, shareholding changes, financial data, and approvals by the board and independent directors. The content focuses on a financing event (capital increase and shareholding change) rather than a financial report or earnings release. The document length is 4154 characters, which is relatively short but contains substantive transaction details, not just a brief announcement or a link to a report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-02-24 Chinese
天士力关于对在任独立董事独立性评估的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion on the independence evaluation of current independent directors of the company, referencing regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange listing rules. It is a formal statement from the board regarding the independence status of specific directors. This fits the category of Board/Management Information (MANG), as it concerns board members and their qualifications rather than financial results or other report types. The document is short and focused on governance-related content, not a full report or announcement of voting results.
2025-02-24 Chinese
天士力2024年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the responsibility of the company's board and auditors regarding internal control over financial reporting as of December 31, 2024. The document contains an auditor's opinion on the effectiveness of internal control over financial reporting. It is a standalone audit report focused on internal control, not a full annual report or interim report. The length is short (771 characters), but the content is a full audit opinion on internal controls, not merely an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2024
2025-02-24 Chinese
天士力第九届董事会第5次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 5th meeting of the 9th Board of Directors of TianShiLi Pharmaceutical Group Co., Ltd. It includes voting results on various reports and proposals such as the 2024 General Manager Work Report, 2024 Board Work Report, 2024 Financial Statements, Profit Distribution Plan, Annual Report, Social Responsibility Report, Internal Control Reports, and other governance and operational matters. The document repeatedly references that the full reports are published separately on the Shanghai Stock Exchange website, indicating this document itself is not the full reports but an announcement of the board meeting decisions and voting outcomes. This fits the definition of a Board/Management Information filing, which covers announcements of board decisions and management matters. The document length is under 5,000 characters and it is not a full financial report but a meeting resolution announcement. Therefore, the correct classification is MANG (Board/Management Information).
2025-02-24 Chinese
天士力关于向关联方转让绍兴天士力生物医药产业股权投资基金合伙企业认缴出资份额暨基金进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the transfer of a fund's subscription shares between related parties of the company. It details the transaction terms, parties involved, fund structure, and risk disclosures. There is no financial statement or comprehensive financial report included, nor is it a transcript, presentation, or regulatory certification. The document is a formal disclosure of a related-party transaction and fund progress, typical of a capital or financing update. The document length is under 5,000 characters, but it contains substantive transaction details rather than just announcing a report publication. Therefore, it fits best under Capital/Financing Update (CAP).
2025-02-24 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.